Candel Therapeutics to Present at November Investor Conferences
Key Highlights
- ➤Candel CEO Paul Peter Tak to join Stifel healthcare conference fireside chat November 10
- ➤Candel CEO Paul Peter Tak to join Jefferies healthcare conference fireside chat November 18
- ➤Aglatimagene holds FDA Fast Track and Regenerative Medicine Advanced Therapy designations for localized prostate cancer
- ➤Linoserpaturev remains in an ongoing phase 1b trial for recurrent high-grade glioma
Expert Statements
Paul Peter Tak, President and Chief Executive Officer of Candel Therapeutics
“will participate in analyst-led fireside discussions and one-on-one meetings at upcoming investor conferences in November 2026”
NEEDHAM, Mass., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel’s President and Chief Executive Officer, will participate in analyst-led fireside discussions and one-on-one meetings at upcoming investor conferences in November 2026.
Stifel 2026 Healthcare Conference (New York, NY) Date / Time: Tuesday, November 10, 2026, at 9:20 AM ET Webcast Link: Stifel / Candel Fireside Chat
Get started
Create a free account to read the full story.